SCHEMBL2270565

SCHEMBL2270565

COc1cccc(C(=O)Nc2cc(-c3ccccc3)ccc2C(=O)O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
POLB P06746 1/20 0.67
HDAC2 Q92769 2/20 0.65
PYGM P11217 1/20 0.62
ACLY P53396 2/20 0.60
RAB9A P51151 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
NPC1 O15118 3/20 0.60
ALDH1A1 P00352 1/20 0.60
TRPV1 Q8NER1 1/20 0.58
SUCNR1 Q9BXA5 1/20 0.58
KCNK3 O14649 1/20 0.57
KCNK9 Q9NPC2 1/20 0.57
FABP1 P07148 1/20 0.56
TP53 P04637 1/20 0.56
MAPT P10636 1/20 0.56
PLAU P00749 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2271137 0.94 HDAC2 (0.74) MEN1KMT2APOLBHDAC2PYGM
SCHEMBL2275393 0.89 HDAC2 (0.73) MEN1KMT2AHDAC2ACLYRAB9A
SCHEMBL2270661 0.88 ACLY (0.58) MEN1KMT2APOLBHDAC2ACLY
SCHEMBL2269165 0.88 MEN1 (0.69) MEN1KMT2AHDAC2ACLYRAB9A
SCHEMBL2275720 0.87 SUCNR1 (0.73) MEN1KMT2AHDAC2ACLYRAB9A
SCHEMBL14075227 0.86 MEN1 (0.78) MEN1KMT2APYGMRAB9ASMN1; SMN2
SCHEMBL12369428 0.85 HDAC2 (0.72) MEN1KMT2APOLBHDAC2RAB9A
SCHEMBL2271177 0.85 PYGM (0.72) MEN1KMT2APYGMRAB9ASMN1; SMN2
SCHEMBL1315613 0.85 HDAC2 (0.56) MEN1KMT2APOLBHDAC2PYGM
SCHEMBL2275453 0.84 ACLY (0.76) MEN1KMT2AHDAC2ACLYRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885POLB 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.